NovaBay Pharmaceuticals Completes 34 Patient Phase 2B Clinical Study

by Business Wire • 2015/11/04 • 0 Comments

EMERYVILLE, Calif.--(BUSINESS WIRE)--NovaBay® Pharmaceuticals, Inc. (NYSE MKT: NBY), a biopharmaceutical company focusing on commercializing and developing non-antibiotic antimicrobial products for the global eye care market, announces plans to report results from a clinical study with its proprietary anti-microbial compound auriclosene (NVC-422) to reduce urinary catheter blockage and encrustation in patients with long-term indwelling urinary catheters in early December. Due to spinal cord inj

← Laryngeal Mask for Keratoplasty Anesthesia Safe, Effective

Aerie Pharmaceuticals to Host Investor and Media Briefing During the 2015 American Academy of Ophthalmology Annual Meeting on November 13, 2015 →

Post navigation